Cancer Letters
Volume 295, Issue 1 , Pages 27-37 , 1 September 2010

A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells

  • Hao Liu
    • ,
  • Anmin Chen
    • ,
  • Fengjing Guo

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Liberalization Street, No. 1095, 430030 Wuhan, China. Tel.: +86 27 8670 8550; fax: +86 27 8364 6605.
    • ,
  • Lin Yuan

Received 30 November 2009 ,Revised 28 January 2010 ,Accepted 11 February 2010.

References 

  1. Buijs JT, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 2009;273:177–193
  2. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, et al. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 1999;5:2271–2277
  3. Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer. 1997;3:605–611
  4. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression using pooled sample expression profiling. J. Natl. Cancer Inst. 2002;94:513–521
  5. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002;62:3417–3427
  6. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004;10:184–190
  7. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Brit. J. Cancer. 2004;90:1877–1881
  8. Macrì A, Versaci A, Lupo G, Trimarchi G, Tomasello C, Loddo S, et al. Role of osteopontin in breast cancer patients. Tumori. 2009;95:48–52
  9. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer. 2009;64:263–270
  10. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001;171:215–222
  11. Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett. 2008;272:148–159
  12. Jain A, McKnight DA, Fisher LW, Humphreys EB, Mangold LA, Partin AW, et al. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin. Cancer Res. 2009;15:5199–5207
  13. Tuck AB, Arsenault DM, O’Malley FP, Hota C, Ling MC, Wilson SM, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 1999;18:4237–4246
  14. Adwan H, Bauerle TJ, Berger MR. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 2004;11:109–120
  15. Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int. J. Oncol. 2004;24:1234–1235
  16. Yamate T, Kohri K, Umekawa T, Iguchi M, Kurita T. Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin-Darby canine kidney cell. J. Urol. 1998;160:1506–1512
  17. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner. Res. 2001;16:652–659
  18. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Brit. J. Cancer. 2000;83:156–163
  19. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol. Cancer. 2007;6:18
  20. Weber GF, Akshar S, Glimcher MJ, Cantor H. Receptor-Ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509–519
  21. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, et al. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA. 1997;94:9308–9313
  22. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA Aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol. Ther. 2009;17:153–161
  23. Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J. Cell Biochem. 2009;108:272–284
  24. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin. Cancer Res. 2008;14:7470–7480
  25. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappaB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 2001;276:44926–44935
  26. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/I kappaBalpha kinase-dependent nuclear factor kappa B-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 2004;279:38921–38935
  27. Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 2006;66:883–888
  28. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997;278:860–866
  29. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005;26:741–751
  30. Butler WT. The nature and significance of osteopontin. Connect. Tissue Res. 1989;23:123–136
  31. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003;198:107–117
  32. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475–1482
  33. Naqvi AR, Islan MN, Choudhury NR, Haq QM. The fascinating world of RNA interference. Int. J. Biol. Sci. 2009;5:97–117
  34. Song J, Giang A, Lu Y, Pang S, Chiu R. Multiple shRNA expressing vector enhances efficiency of gene silencing. BMB Rep. 2008;41:358–362
  35. Chang H. RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Ther. 2007;14:677–685
  36. Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 2007;25:1435–1443
  37. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–553
  38. Dave RS, Pomerantz RJ. RNA interference on the road to an alternate therapeutic strategy. Rev. Med. Virol. 2003;13:373–385
  39. Tuck AB, Hota C, Wilson SM, Chambers AF. Osteopontin induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene. 2003;22:1198–1205
  40. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell Biochem. 2000;78:465–475
  41. Lin YH, Huang CJ, Chao JR, Chen ST, Lee SF, Yen JJ, et al. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol. Cell Biol. 2000;20:2734–2742
  42. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CA, et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J. Cell Physiol. 2004;198:155–167
  43. Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene. 2005;24:489–501
  44. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 2003;278:28593–28606
  45. Ogata T, Ueyama T, Nomura T, Asada S, Tagawa M, Nakamura T, et al. Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 2007;359:341–347
  46. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol.Chem. 2004;279:11051–11064
  47. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. New Engl. J. Med. 1997;336:1066–1071
  48. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell. 1995;80:573–582
  49. Zhaodan C, William JH, Xiong G. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996;27:1128–1131
  50. Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Baldwin AS. I kappaB interacts with the nuclear localization sequences of the subunits of NF-kappaB: a mechanism for cytoplasmic retention. Genes Dev. 1992;6:1899–1913
  51. Hay RT, Vuillard L, Desterro JM, Rodriguez MS. Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha. Philos. Trans. Roy. Soc. Lond. B. Biol. Sci. 1999;354:1601–1609
  52. Burke JR, Strnad J. The catalytic subunits of IkappaB kinase, IKK-1 and IKK-2, Contain non-equivalent active sites when expressed as homodimers. Biochem. Biophys. Res. Commun. 2002;293:1508–1513

PII: S0304-3835(10)00100-X

doi: 10.1016/j.canlet.2010.02.012

Cancer Letters
Volume 295, Issue 1 , Pages 27-37 , 1 September 2010

Article Tools

* Image Usage & Resolution